Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 176,900 shares of the business’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the completion of the sale, the chief operating officer now owns 668,680 shares of the company’s stock, valued at approximately $7,903,797.60. This represents a 20.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Price Performance

ROIV stock opened at $11.83 on Thursday. The firm’s fifty day simple moving average is $11.91 and its 200-day simple moving average is $11.55. The company has a market capitalization of $8.61 billion, a P/E ratio of 2.09 and a beta of 1.25. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06.

Institutional Trading of Roivant Sciences

Large investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in shares of Roivant Sciences in the 2nd quarter valued at $34,000. Gladius Capital Management LP purchased a new stake in Roivant Sciences during the third quarter worth $35,000. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences during the second quarter worth $36,000. US Bancorp DE boosted its holdings in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP purchased a new stake in Roivant Sciences during the second quarter worth $53,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America boosted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.